Evidence map›Paper›PMID 18644994›Full record

ArticleMolecular cancer therapeutics2008

Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells.

Manesh Chittezhath, Gagan Deep, Rana P Singh, Chapla Agarwal, Rajesh Agarwal

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 72 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Manesh ChittezhathDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Box C238, East 4200 9th Street, Denver, CO 80262, USA.
Gagan Deep
Rana P Singh
Chapla Agarwal
Rajesh Agarwal
Pharmaceutical Biotechnology (Czechia) · CZUniversity of Colorado Cancer Center · US

Funding

Angioprevention of Lung Tumorigenesis by SilibininR01CA113876 · NCI · UNIVERSITY OF COLORADO DENVER · PI AGARWAL, RAJESH · 2005 to 2009
$1.5M
NCI NIH HHS R01 CA113876
6 · The paper itself

Abstract

Recently, we reported that silibinin inhibits primary lung tumor growth and progression in mice and down-regulates inducible nitric oxide synthase (iNOS) expression in tumors; however, the mechanisms of silibinin action are largely not understood. Also, the activation of signaling pathways inducing various transcription factors are associated with lung carcinogenesis and their inhibition could be an effective strategy to prevent and/or treat lung cancer. Herein, we used human lung epithelial carcinoma A549 cells to explore the potential mechanisms and observed strong iNOS expression by cytokine mixture (containing 100 units/mL IFN-gamma + 0.5 ng/mL interleukin-1beta + 10 ng/mL tumor necrosis factor-alpha). We also examined the cytokine mixture-activated signaling cascades, which could potentially up-regulate iNOS expression, and then examined the effect of silibinin (50-200 mumol/L) on these signaling cascades. Silibinin treatment inhibited, albeit to different extent, the cytokine mixture-induced activation of signal transducer and activator of transcription 1 (Tyr(701)), signal transducer and activator of transcription 3 (Tyr(705)), activator protein-1 family of transcription factors, and nuclear factor-kappaB. The results for activator protein-1 were correlated with the decreased nuclear levels of phosphorylated c-Jun, c-Jun, JunB, JunD, phosphorylated c-Fos, and c-Fos. Further, silibinin also strongly decreased cytokine mixture-induced phosphorylation of extracellular signal-regulated kinase 1/2 but only marginally affected JNK1/2 phosphorylation. Silibinin treatment also decreased constitutive p38 phosphorylation in the presence or absence of cytokine mixture. Downstream of these pathways, silibinin strongly decreased cytokine mixture-induced expression of hypoxia-inducible factor-1alpha without any considerable effect on Akt activation. Cytokine mixture-induced iNOS expression was completely inhibited by silibinin. Overall, these results suggest that silibinin could target multiple cytokine-induced signaling pathways to down-regulate iNOS expression in lung cancer cells and that could contribute to its overall cancer preventive efficacy against lung tumorigenesis.

Indexed as

Antineoplastic AgentsCell Line, TumorCytokinesDown-RegulationEnzyme ActivationHumansHypoxia-Inducible Factor 1, alpha SubunitLung NeoplasmsMitogen-Activated Protein KinasesNF-kappa BNitric Oxide Synthase Type IIProto-Oncogene Proteins c-aktSignal TransductionSilybinSilymarinSTAT1 Transcription FactorAntineoplastic AgentsCytokinesHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMitogen-Activated Protein KinasesNF-kappa BNitric Oxide Synthase Type IINOS2 protein, humanProto-Oncogene Proteins c-aktSilybinSilymarinSTAT1 protein, humanSTAT1 Transcription FactorSTAT3 protein, humanSTAT3 Transcription FactorTranscription Factor AP-1

Identifiers

PMID18644994
PMCPMC2587409
OpenAlexW2135263177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.